Header

News Archive

The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.

Showing 38 results

June 2025

Media Release Jun 18, 2025
Health Canada approves Novartis' KISQALI® for HR+/HER2- early breast cancer patients at high risk of recurrence

Despite endocrine therapy (ET), the risk of recurrence for people diagnosed with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) early breast cancer (eBC…
Media Release Jun 10, 2025
The Novartis Oncology Young Canadian Investigator Awards (NOYCIA) returns for its 22nd year at ASCO 2025

For over two decades, NOYCIA has fueled emerging research in Canada, driving scientific knowledge in cancerMontreal, QC – June 10, 2025 – Novartis Canada is pleased to announce the winners…

May 2025

Media Release May 14, 2025
Novartis Canada extends Health Equity Initiative effort, fueling innovation and impact for second year

• Applications are now being accepted, with $500,000 in grants to be awarded to projects focused on improving health equity in CanadaMontreal, Quebec, May 14, 2025 – Novartis…

February 2025

Media Release Feb 13, 2025
Novartis receives Health Canada approval for Fabhalta® oral treatment for adult patients with PNH

Fabhalta® is the first oral monotherapy for previously treated and treatment-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH)1,2 Significant unmet need remains in PNH, a chronic, rare…

January 2025

Media Release Jan 16, 2025
First patient in Ontario treated with publicly funded Pluvicto™ in a major step forward for advanced prostate cancer care

Ontario is the first province in Canada to offer public reimbursement for Pluvicto™, a targeted radioligand therapy for patients with progressive PSMA-positive metastatic castration-resistant…

December 2024

November 2024

Media Release Nov 15, 2024
Novartis Canada disappointed with outcome of pCPA negotiations for metastatic castration resistant prostate cancer treatment PLUVICTO™

Montreal, November 15, 2024 – Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is extremely disappointed that negotiations for PLUVICTO™ (lutetium (177Lu) vipivotide tetraxetan injection), a…

August 2024

Media Release Aug 20, 2024
Novartis celebrates Canada-wide implementation of newborn screening for spinal muscular atrophy

Prioritization of screening programs for spinal muscular atrophy (SMA) will ensure early diagnosis across Canada and bring lasting impact to babies and caregivers Montreal, August 20, 2024 —…

July 2024

Media Release Jul 08, 2024
Novartis Canada launches $500,000 funding initiative to improve health equity in Canada

Montréal, QC, July 8, 2024 – Novartis Pharmaceuticals Canada Inc. (Novartis) today announced the launch of a new health equity initiative, aimed at addressing health disparities and promoting…

June 2024

Media Release Jun 11, 2024
The Novartis Oncology Young Canadian Investigator Awards (NOYCIA) returns for its 21st year at ASCO 2024

NOYCIA recognizes excellence in Canadian oncology research as part of Novartis Canada’s commitment to reimagining medicineMontreal, QC, June 11, 2024 – Novartis Canada is pleased to announce the…

May 2024

Media Release May 27, 2024
NOVARTIS CANADA AND CLARIUS MOBILE HEALTH CHALLENGE STANDARD OF CARE FOR PSORIATIC ARTHRITIS WITH NEW PARTNERSHIP

Psoriatic arthritis is a chronic, autoimmune disease form of arthritis that causes joint inflammation (swelling, pain, stiffness) and occurs with skin condition psoriasis. It can also affect the…